A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 72, Issue 1, 2009, Pages 105-110

  Pabla, Dimple ^a   Akhlaghi, Fatemeh ^a   Zia, Hossein ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Bioequivalence; Dissolution; ICP MS; Levothyroxine; pH; Proton pump inhibitors; Sandoz; Synthroid ; Tirosint

Indexed keywords

LEVOTHYROXINE SODIUM; PROTON PUMP INHIBITOR; SURFACTANT; TIROSINT; UNCLASSIFIED DRUG;

ARTICLE; BIOEQUIVALENCE; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; MASS SPECTROMETRY; PH MEASUREMENT; STOMACH PH;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HYDROGEN-ION CONCENTRATION; MASS SPECTROMETRY; MODELS, CHEMICAL; MODELS, STATISTICAL; SODIUM DODECYL SULFATE; SOLUBILITY; SURFACE-ACTIVE AGENTS; THERAPEUTIC EQUIVALENCY; THYROXINE; TIME FACTORS;

EID: 63149114224     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.10.008     Document Type: Article

References (36)

1. Singer P.A., Cooper D.S., Levy E.G., Ladenson P.W., Braverman L.E., Daniels G., Greenspan F.S., McDougall I.R., and Nikolai T.F. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 273 (1995) 808-812
2. Carr D., McLeod D.T., Parry G., and Thornes H.M. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin. Endocrinol. (Oxf.) 28 (1988) 325-333
3. Klein I., and Ojamaa K. Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 344 (2001) 501-509
4. Blakesley V., Awni W., Locke C., Ludden T., Granneman G.R., and Braverman L.E. Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable?. Thyroid 14 (2004) 191-200
5. Blakesley V.A. Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate. AAPS J. 7 (2005) E42-E46
6. Hennessey J.V. Levothyroxine a new drug? Since when? How could that be?. Thyroid 13 (2003) 279-282
7. Klein I., and Danzi S. Evaluation of the therapeutic efficacy of different levothyroxine preparations in the treatment of human thyroid disease. Thyroid 13 (2003) 1127-1132
8. Mayor G.H., Orlando T., and Kurtz N.M. Limitations of levothyroxine bioequivalence evaluation: analysis of an attempted study. Am. J. Ther. 2 (1995) 417-432
9. Wartofsky L. Levothyroxine: therapeutic use and regulatory issues related to bioequivalence. Expert Opin. Pharmacother. 3 (2002) 727-732
10. Olveira G., Almaraz M.C., Soriguer F., Garriga M.J., Gonzalez-Romero S., Tinahones F., and Adana M.S.Ruiz.de. Altered bioavailability due to changes in the formulation of a commercial preparation of levothyroxine in patients with differentiated thyroid carcinoma. Clin. Endocrinol. (Oxf.) 46 (1997) 707-711
11. Shroff A.P., and Jones J.K. Standards for levothyroxine preparations. JAMA 244 (1980) 658-659
12. CDER, Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations, US FDA, 2002.
13. CDER, Guidance for Industry: Waiver of in Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, US FDA, 2000.
14. USP, Levothyroxine sodium tablets, in: The United States Pharmacopoeia, United States Pharmacopoeia Convention Inc., Rockville, MD, 2007, pp. 2470-2471.
15. Hays M.T. Localization of human thyroxine absorption. Thyroid 1 (1991) 241-248
16. Centanni M., Gargano L., Canettieri G., Viceconti N., Franchi A., Delle F.G., and Annibale B. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N. Engl. J. Med. 354 (2006) 1787-1795
17. Sachmechi I., Reich D.M., Aninyei M., Wibowo F., Gupta G., and Kim P.J. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr. Pract. 13 (2007) 345-349
18. Pabla D., Akhlaghi F., Ahmed A., and Zia H. Development and validation of an inductively coupled plasma mass spectrometry method for quantification of levothyroxine in dissolution studies. Rapid Commun. Mass Spectrom. 22 (2008) 993-996
19. CDER, Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, US FDA, 1997.
20. Moore J.W., and Flanner H.H. Mathematical comparison of dissolution profiles. Pharm. Tech. 20 (1996) 64-74
21. Top 200 brand drugs by unit in 2007. Available from: .
22. Volpato N.M., Silva R.L., Brito A.P., Goncalves J.C., Vaisman M., and Noel F. Multiple level C in vitro/in vivo correlation of dissolution profiles of two l-thyroxine tablets with pharmacokinetics data obtained from patients treated for hypothyroidism. Eur. J. Pharm. Sci. 21 (2004) 655-660
23. Montaser A. Inductively Coupled Plasma Mass Spectrometry (1998), Wiley-VCH, New York
24. Haldimann M., Zimmerli B., Als C., and Gerber H. Direct determination of urinary iodine by inductively coupled plasma mass spectrometry using isotope dilution with iodine-129. Clin. Chem. 44 (1998) 817-824
25. Takaku Y.S., Masuda T., and Igarashi Y. Iodine determination in natural and tap water using inductively coupled plasma mass spectrometry. Anal. Chem. 11 (1995) 823-827
26. Vanhoe H., Van A.F., Versieck J., and Dams R. Effect of solvent type on the determination of total iodine in milk powder and human serum by inductively coupled plasma mass spectrometry. Analyst 118 (1993) 1015-1019
27. Sacher F., Raue B., and Brauch H.J. Analysis of iodinated X-ray contrast agents in water samples by ion chromatography and inductively-coupled plasma mass spectrometry. J. Chromatogr. A 1085 (2005) 117-123
28. Sandoz Inc., Levothyroxine Sodium Tablets, USP (Package Insert), 2007.
29. ® (Levothyroxine Sodium Tablets, USP) 03-5443-R2-Rev. (Package Insert), 2006.
30. CDER, Orange Book, 2008. Available from: .
31. Center for Drug Evaluation and Research, Application Number(s) 21-342/S-003, 2007. Available from: .
32. Request that the Commissioner of Food and Drug Take Action Described Methodology for Oral Levothyroxine Sodium Drug Products, 2007. Available from: .
33. Equivalence of Levothyroxine Sodium Products: Joint Public Meeting, 2007. Available from: .
34. American Thyroid Association, Thyroid Experts Warn of Clinically Important Differences in Potency of FDA-Approved Levothyroxine Products, 2007. Available from: .
35. Won C.M. Kinetics of degradation of levothyroxine in aqueous solution and in solid state. Pharm. Res. 9 (1992) 131-137
36. TM, 2007. Available from: .